{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T13:43:11Z","timestamp":1778852591217,"version":"3.51.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01418-w","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:20:31Z","timestamp":1770787231000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Perioperative Chemoimmunotherapy vs. Chemotherapy Alone for Gastroesophageal Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4107-1318","authenticated-orcid":false,"given":"Lorrany Larisse Costa","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca Ferreira","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca Gonzaga","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valbert Oliveira","family":"Costa Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Macambira","family":"Noronha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filipe Luis Vasconcelos","family":"Visani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ot\u00e1vio","family":"Al-Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"3","key":"1418_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seminoncol.2025.152341","volume":"52","author":"SP Pradhan","year":"2025","unstructured":"Pradhan SP, Gadnayak A, Pradhan SK, Epari V. Epidemiology and prevention of gastric cancer: a comprehensive review. Semin Oncol. 2025;52(3):152341. https:\/\/doi.org\/10.1016\/j.seminoncol.2025.152341.","journal-title":"Semin Oncol"},{"issue":"1","key":"1418_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.17849\/insm-48-1-1-19.1","volume":"48","author":"AF Milano","year":"2019","unstructured":"Milano AF. 20-Year comparative survival and mortality of cancer of the stomach by Age, Sex, Race, Stage, Grade, cohort entry Time-Period, disease duration & selected ICD-O-3 oncologic phenotypes: a systematic review of 157,258 cases for diagnosis years 1973\u20132014: (SEER*Stat 8.3.4). J Insur Med. 2019;48(1):5\u201323. https:\/\/doi.org\/10.17849\/insm-48-1-1-19.1.","journal-title":"J Insur Med"},{"issue":"10184","key":"1418_CR3","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"9","key":"1418_CR4","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197\u2013203. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6762.","journal-title":"JAMA Oncol"},{"issue":"3","key":"1418_CR5","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1418_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(24)00676-4","volume":"26","author":"X Zhang","year":"2025","unstructured":"Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial. Lancet Oncol. 2025;26(3):312\u20139. https:\/\/doi.org\/10.1016\/S1470-2045(24)00676-4.","journal-title":"Lancet Oncol"},{"issue":"19","key":"1418_CR7","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa2405195","volume":"391","author":"T Leong","year":"2024","unstructured":"Leong T, Smithers BM, Michael M, et al. Preoperative chemoradiotherapy for resectable gastric cancer. N Engl J Med. 2024;391(19):1810\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2405195.","journal-title":"N Engl J Med"},{"issue":"5","key":"1418_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1001\/jamasurg.2022.0182","volume":"157","author":"GZ Li","year":"2022","unstructured":"Li GZ, Doherty GM, Wang J. Surgical management of gastric cancer: a review. JAMA Surg. 2022;157(5):446\u201354. https:\/\/doi.org\/10.1001\/jamasurg.2022.0182.","journal-title":"JAMA Surg"},{"issue":"7","key":"1418_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21(7):509\u201328. https:\/\/doi.org\/10.1038\/s41573-021-00345-8.","journal-title":"Nat Rev Drug Discov"},{"issue":"10294","key":"1418_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"issue":"4","key":"1418_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1200\/JCO.23.00975","volume":"42","author":"S Lorenzen","year":"2024","unstructured":"Lorenzen S, G\u00f6tze TO, Thuss-Patience P, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II\/III dante\/IKF-s633 trial. J Clin Oncol. 2024;42(4):410\u201320. https:\/\/doi.org\/10.1200\/JCO.23.00975.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1418_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2503701","volume":"393","author":"YY Janjigian","year":"2025","unstructured":"Janjigian YY, Al-Batran SE, Wainberg ZA, et al. Perioperative durvalumab in gastric and gastroesophageal junction cancer. N Engl J Med. 2025;393(3):217\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2503701.","journal-title":"N Engl J Med"},{"issue":"2","key":"1418_CR13","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(23)00541-7","volume":"25","author":"K Shitara","year":"2024","unstructured":"Shitara K, Rha SY, Wyrwicz LS, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol. 2024;25(2):212\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(23)00541-7.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1418_CR14","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.21037\/tcr-2024-2631","volume":"14","author":"CR Li","year":"2025","unstructured":"Li CR, Lin MZ, Li B, et al. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in patients with resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis. Transl Cancer Res. 2025;14(6):3373\u201399. https:\/\/doi.org\/10.21037\/tcr-2024-2631.","journal-title":"Transl Cancer Res"},{"key":"1418_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.112576","volume":"138","author":"D Huang","year":"2024","unstructured":"Huang D, Sun F, Ke L, Li S. Perioperative immune checkpoint inhibitors combined with chemotherapy versus chemotherapy for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials. Int Immunopharmacol. 2024;138:112576. https:\/\/doi.org\/10.1016\/j.intimp.2024.112576.","journal-title":"Int Immunopharmacol"},{"key":"1418_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1418_CR17","unstructured":"Higgins JPT, Thomas J, Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions. 2nd Edition. Chichester (UK): John Wiley & Sons, 2019. https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current. Accessed August 02, 2025."},{"issue":"1","key":"1418_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111. https:\/\/doi.org\/10.1186\/s12874-021-01308-8.","journal-title":"BMC Med Res Methodol"},{"key":"1418_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16.","journal-title":"Trials"},{"key":"1418_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"1418_CR21","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"7650","key":"1418_CR22","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"issue":"1","key":"1418_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10125-1","volume":"22","author":"MY Lai","year":"2022","unstructured":"Lai MY, Kang SY, Sun YT, et al. Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer. BMC Cancer. 2022;22(1):1031. https:\/\/doi.org\/10.1186\/s12885-022-10125-1.","journal-title":"BMC Cancer"},{"key":"1418_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783243","volume":"12","author":"JL Lin","year":"2022","unstructured":"Lin JL, Lin JX, Lin JP, et al. Safety and efficacy of camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion. Front Immunol. 2022;12:783243. https:\/\/doi.org\/10.3389\/fimmu.2021.783243.","journal-title":"Front Immunol"},{"issue":"6","key":"1418_CR25","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1007\/s10120-023-01431-z","volume":"26","author":"X Huang","year":"2023","unstructured":"Huang X, Fang J, Huang L, et al. SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score-matched analysis. Gastric Cancer. 2023;26(6):1040\u201350. https:\/\/doi.org\/10.1007\/s10120-023-01431-z.","journal-title":"Gastric Cancer"},{"key":"1418_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1122121","volume":"14","author":"Q Jiang","year":"2023","unstructured":"Jiang Q, Liu W, Zeng X, et al. Safety and efficacy of tislelizumab plus chemotherapy versus chemotherapy alone as neoadjuvant treatment for patients with locally advanced gastric cancer: real-world experience with a consecutive patient cohort. Front Immunol. 2023;14:1122121. https:\/\/doi.org\/10.3389\/fimmu.2023.1122121.","journal-title":"Front Immunol"},{"issue":"8","key":"1418_CR27","first-page":"3559","volume":"13","author":"H Xiong","year":"2023","unstructured":"Xiong H, Li Y. Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer [Published online August 15, 2023]. Am J Cancer Res. 2023;13(8):3559\u201370.","journal-title":"Am J Cancer Res"},{"key":"1418_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101657","volume":"31","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang C, Hou H, et al. Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: a single-centre retrospective study. Transl Oncol. 2023;31:101657. https:\/\/doi.org\/10.1016\/j.tranon.2023.101657.","journal-title":"Transl Oncol"},{"issue":"2","key":"1418_CR29","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41591-023-02721-w","volume":"30","author":"SQ Yuan","year":"2024","unstructured":"Yuan SQ, Nie RC, Jin Y, et al. Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial. Nat Med. 2024;30(2):552\u20139. https:\/\/doi.org\/10.1038\/s41591-023-02721-w.","journal-title":"Nat Med"},{"issue":"4","key":"1418_CR30","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1200\/JCO.24.00795","volume":"43","author":"C Li","year":"2025","unstructured":"Li C, Tian Y, Zheng Y, et al. Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J Clin Oncol. 2025;43(4):464\u201374. https:\/\/doi.org\/10.1200\/JCO.24.00795.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1418_CR31","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1097\/JS9.0000000000001468","volume":"110","author":"YQ Sun","year":"2024","unstructured":"Sun YQ, Zhong Q, Lv CB, et al. The safety and efficacy of neoadjuvant immunochemotherapy following laparoscopic gastrectomy for gastric cancer: a multicentre real-world clinical study. Int J Surg. 2024;110(8):4830\u20138. https:\/\/doi.org\/10.1097\/JS9.0000000000001468.","journal-title":"Int J Surg"},{"issue":"11","key":"1418_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03802-6","volume":"73","author":"H Cui","year":"2024","unstructured":"Cui H, Yang Y, Song L, et al. The short-term efficacy of neoadjuvant SOX versus SOX plus immune checkpoint inhibitor following laparoscopic gastrectomy for locally advanced gastric cancer: a multicenter retrospective cohort study in China. Cancer Immunol Immunother. 2024;73(11):216. https:\/\/doi.org\/10.1007\/s00262-024-03802-6.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"1418_CR33","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.4251\/wjgo.v16.i4.1281","volume":"16","author":"ZH Bao","year":"2024","unstructured":"Bao ZH, Hu C, Zhang YQ, et al. Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers. World J Gastrointest Oncol. 2024;16(4):1281\u201395. https:\/\/doi.org\/10.4251\/wjgo.v16.i4.1281.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"1418_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44309-5","volume":"15","author":"JX Lin","year":"2024","unstructured":"Lin JX, Tang YH, Zheng HL, et al. Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial. Nat Commun. 2024;15(1):41. https:\/\/doi.org\/10.1038\/s41467-023-44309-5.","journal-title":"Nat Commun"},{"issue":"4","key":"1418_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/CM9.0000000000003028","volume":"138","author":"G Xu","year":"2025","unstructured":"Xu G, Liu T, Shen J, Guan Q. Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs. chemotherapy alone in HER2(-) locally advanced gastric cancer: A propensity score-matched cohort study. Chin Med J (Engl). 2025;138(4):459\u201371. https:\/\/doi.org\/10.1097\/CM9.0000000000003028.","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"1418_CR36","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v17.i6.106361","volume":"17","author":"QX Chen","year":"2025","unstructured":"Chen QX, Zhang YB, Zeng WM, et al. Efficacy and safety of sintilimab combined with nab-paclitaxel plus S-1 for neoadjuvant treatment of locally advanced gastric cancer. World J Gastrointest Surg. 2025;17(6):106361. https:\/\/doi.org\/10.4240\/wjgs.v17.i6.106361.","journal-title":"World J Gastrointest Surg"},{"key":"1418_CR37","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251346423","volume":"17","author":"Y Chen","year":"2025","unstructured":"Chen Y, Lin Y, Xu Y, et al. Immune checkpoint inhibitors improve the efficacy of neoadjuvant chemotherapy in advanced gastric cancer: a retrospective cohort study. Ther Adv Med Oncol. 2025;17:17588359251346423. https:\/\/doi.org\/10.1177\/17588359251346423.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"1418_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-025-03710-8","volume":"23","author":"C Li","year":"2025","unstructured":"Li C, Duan Y, Zhou S, Tang T, Yang Y, Zhou L. Evaluating the efficacy and safety of neoadjuvant immunochemotherapy versus chemotherapy in locally advanced gastric cancer undergoing radical gastrectomy: a retrospective study. World J Surg Oncol. 2025;23(1):121. https:\/\/doi.org\/10.1186\/s12957-025-03710-8.","journal-title":"World J Surg Oncol"},{"key":"1418_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1497004","volume":"16","author":"N Zhang","year":"2025","unstructured":"Zhang N, Li C, Zhao Z, et al. Immune microenvironment features underlying the superior efficacy of neoadjuvant immunochemotherapy over chemotherapy in local advanced gastric cancer. Front Immunol. 2025;16:1497004. https:\/\/doi.org\/10.3389\/fimmu.2025.1497004.","journal-title":"Front. Immunol"},{"issue":"7517","key":"1418_CR40","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","journal-title":"Nature"},{"key":"1418_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007104","volume":"11","author":"G Randon","year":"2023","unstructured":"Randon G, Aoki Y, Cohen R, Provenzano L, Nasca V, Klempner SJ, et al. Outcomes and a prognostic classifier in patients with microsatellite instability-high metastatic gastric cancer receiving PD-1 blockade. J Immunother Cancer. 2023;11:e007104. https:\/\/doi.org\/10.1136\/jitc-2023-007104.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1418_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14010218","volume":"14","author":"HY Yu","year":"2022","unstructured":"Yu HY, Li CP, Huang YH, et al. Microsatellite instability, Epstein-Barr virus, and programmed cell death ligand 1 as predictive markers for immunotherapy in gastric cancer. Cancers (Basel). 2022;14(1):218. https:\/\/doi.org\/10.3390\/cancers14010218.","journal-title":"Cancers (Basel)"},{"key":"1418_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1529637","volume":"16","author":"C Wang","year":"2025","unstructured":"Wang C, Wang Q, Zhou J, Zhou A, Wu X, Yu G, et al. Insights into immune-related adverse events in colorectal cancer patients receiving neoadjuvant immunotherapy: findings from a multicenter registry study. Front Immunol. 2025;16:1529637. https:\/\/doi.org\/10.3389\/fimmu.2025.1529637.","journal-title":"Front Immunol"},{"issue":"35","key":"1418_CR44","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37(35):3392\u2013400. https:\/\/doi.org\/10.1200\/JCO.19.01124.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1418_CR45","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"issue":"2","key":"1418_CR46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1200\/JCO.22.00686","volume":"41","author":"T Andr\u00e9","year":"2023","unstructured":"Andr\u00e9 T, Tougeron D, Piessen G, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair\/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol. 2023;41(2):255\u201365. https:\/\/doi.org\/10.1200\/JCO.22.00686.","journal-title":"J Clin Oncol"},{"key":"1418_CR47","unstructured":"Gruppo Oncologico del Nord-Ovest. TremelImumab aNd Durvalumab For the Non-operative Management (NOM) of MSI-high Resectable GC\/\u200bGEJC. (INFINITY). https:\/\/www.clinicaltrials.gov\/study\/NCT04817826. Accessed August 12, 2025."},{"issue":"8","key":"1418_CR48","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S2468-1253(24)00156-0","volume":"9","author":"YK Kang","year":"2024","unstructured":"Kang YK, Terashima M, Kim YW, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(8):705\u201317. https:\/\/doi.org\/10.1016\/S2468-1253(24)00156-0.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01418-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01418-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01418-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:20:34Z","timestamp":1770787234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-026-01418-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01418-w","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"6 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}